Car-T Central
  • CAR-T Fundamentals
  • CAR-T in Australia
  • Clinical Management
  • Expert Opinion
  • About Us
  • Register
Car-T Central
  • CAR-T Fundamentals
  • CAR-T in Australia
  • Clinical Management
  • Expert Opinion
  • About Us
  • Register

axicabtagene ciloleucel

All EHA CAR-T Abstracts

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Granulocyte colony stimulating factor (GCSF) administration does not affect prevalence and severity of CRS, ICANS nor outcome in patients with R/R large B cells lymphomas treated by CD19 CAR-T

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Multi-technique follow-up of lymphoma patients undergoing commercial CAR-T cell therapy: experience from a single centre

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

TMTV correlates with early progression (EP) after CD19 CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

An assessment of the reimbursement landscape to CAR T-cell therapy in Europe

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Interim analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-hodgkin lymphoma

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Comparison of safety management costs across chimeric antigen receptor (CAR) T cell therapies in relapsed or refractory large B-cell lymphoma

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma – the Munich real life experience

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Tumor microenvironment and elevated IL6 are associated with severe toxicity in patients with LBL treated with axicabtagene ciloleucel

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Outcome of high-grade lymphoma patients treated with CD19 CAR-T – updated real-world experience in the UK

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Posts navigation

Previous
Privacy Policy © Copyright Bastion Brands 2022